Business Context and Reporting Period
This Form 8-K is filed by AspenBio Pharma, Inc., not Riot Platforms, Inc., as indicated in the metadata. The report covers events occurring on December 19, 2008, with the filing date of December 22, 2008. The document reports the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation.
Material Changes
The primary material change reported is the appointment of John H. Landon to the Board of Directors to fill a vacancy. Mr. Landon will serve until the 2009 Annual Meeting of Shareholders or until his successor is elected. He was not initially appointed to any board committees.
Management Commentary and Compensation
Mr. Landon brings over 30 years of experience, including roles at DuPont, Cholestech Corporation, and Digene Corporation. His compensation package includes:
- Stock Options: 67,035 options to acquire common shares at an exercise price of $5.87 per share. These vest annually in arrears over three years and expire in ten years.
- Cash Compensation: $1,000 per month as an independent director.
The filing references a press release dated December 22, 2008, attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the registrant name is AspenBio Pharma, Inc., not Riot Platforms, Inc.
- Confirm the vesting schedule and expiration date of the 67,035 stock options granted to Mr. Landon.
- Review the attached press release (Exhibit 99.1) for additional context on the board expansion.
- Monitor future filings for Mr. Landon's potential assignment to board committees.